Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8C1V

SARS-CoV-2 S-trimer (3 RBDs up) bound to TriSb92, fitted into cryo-EM map

8C1V の概要
エントリーDOI10.2210/pdb8c1v/pdb
EMDBエントリー16383
分子名称Spike glycoprotein, Sb92, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
機能のキーワードsars-cov-2 spike, sherpabody, viral protein, coronavirus
由来する生物種Severe acute respiratory syndrome coronavirus 2
詳細
タンパク質・核酸の鎖数6
化学式量合計404600.45
構造登録者
Huiskonen, J.T.,Rissanen, I.,Hannula, L. (登録日: 2022-12-21, 公開日: 2023-04-19, 最終更新日: 2024-11-20)
主引用文献Makela, A.R.,Ugurlu, H.,Hannula, L.,Kant, R.,Salminen, P.,Fagerlund, R.,Maki, S.,Haveri, A.,Strandin, T.,Kareinen, L.,Hepojoki, J.,Kuivanen, S.,Levanov, L.,Pasternack, A.,Naves, R.A.,Ritvos, O.,Osterlund, P.,Sironen, T.,Vapalahti, O.,Kipar, A.,Huiskonen, J.T.,Rissanen, I.,Saksela, K.
Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants.
Nat Commun, 14:1637-1637, 2023
Cited by
PubMed Abstract: The emergence of increasingly immunoevasive SARS-CoV-2 variants emphasizes the need for prophylactic strategies to complement vaccination in fighting the COVID-19 pandemic. Intranasal administration of neutralizing antibodies has shown encouraging protective potential but there remains a need for SARS-CoV-2 blocking agents that are less vulnerable to mutational viral variation and more economical to produce in large scale. Here we describe TriSb92, a highly manufacturable and stable trimeric antibody-mimetic sherpabody targeted against a conserved region of the viral spike glycoprotein. TriSb92 potently neutralizes SARS-CoV-2, including the latest Omicron variants like BF.7, XBB, and BQ.1.1. In female Balb/c mice intranasal administration of just 5 or 50 micrograms of TriSb92 as early as 8 h before but also 4 h after SARS-CoV-2 challenge can protect from infection. Cryo-EM and biochemical studies reveal triggering of a conformational shift in the spike trimer as the inhibitory mechanism of TriSb92. The potency and robust biochemical properties of TriSb92 together with its resistance against viral sequence evolution suggest that TriSb92 could be useful as a nasal spray for protecting susceptible individuals from SARS-CoV-2 infection.
PubMed: 36964125
DOI: 10.1038/s41467-023-37290-6
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (2.9 Å)
構造検証レポート
Validation report summary of 8c1v
検証レポート(詳細版)ダウンロードをダウンロード

243083

件を2025-10-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon